TP53 and neoplasm: Thus, the finding that the ability of TP53 mutant tumor cells to uptake 10B is less dependent on tumor heterogeneity than TP53 wild-type tumor cells supports that BNCT has great promise for controlling TP53 mutant tumors that are resistant to low-LET radiation.